The use of the skin as a route of delivery into the systemic circulation has been exploited since the 1950s with the development of ointments containing agents such as nitroglycerin and salicylates. This has been extended since the early 1980s to hormone replacement therapy with the development of skin patches and gels. The skin affords a major barrier and the mechanisms of drug transport across it are discussed. Delivery of oestradiol and progestogens are discussed.
. ReichekNGoldsteinRERedwoodDRSustained effects of nitroglycerin ointment in patients with angina pectoris. Circulation1974; 50: 348–352.
2.
. ScheupleinRJBlankIHPermeability of the skin. Physiol Rev1971; 51: 702–747.
3.
. ClearyGWTransdermal delivery systems: a medical rationale. In: TopicalDrug Bioevailability, Biosquivalence, and Penetration (ShahVPMalbachHI, eds.) 1993Plenum PressNew York, 17–68.
4.
. WaltersKATransdermal drug delivery systems. In: Encyclopedia of Pharmaceutical Technology, Volume 15 (SwarbrickJBoylanJC eds.) 1997Marcel DekkerNew York, pp 253–292.
5.
. AndersonBDProdrugs and their topical use. In: Topical Drug Bioavailability, Bioequivalence, and Penetration (ShahVPMaibachHI eds.) 1993Plenum PressNew York, pp 69–89.
6.
. GreenPGFlanaganMShrootBGuyRHIontophoretic drug delivery. In: Pharmaceutical Skin Penetration Enhancement (WaltersKAHadgraftJ eds.), 1993Marcel DekkerNew York, pp 311–333,.
7.
. McElnayJCBensonHAEHadgraftJMurphyTMThe use of ultrasound in skin penetration enhancement. In: Pharmaceutical Skin Penetration Enhancement (WaltersKAHadgraftJ eds.), 1993Marcel DekkerNew York, pp 293–309.
8.
. WaltersKAHadgraftJ, eds. Pharmaceutical Skin Penetration Enhancement, 1993Marcel DekkerNew York
9.
. SunT-TGreenH.Differentiation of the epidermal keratinocytes in cell culture: formation of the cornified envelope. Cell1976; 9: 515–521.
10.
. WertzPWDowningDTGlycolipids in mammalian epidermis: structure and function in the water barrier. Science1982; 217: 1261–1262.
11.
. HadgraftJWaltersKAGuyRHEpidermal lipids and topical drug delivery. Sem Dermatol1992; 11: 139–144.
12.
. YanoTNakagawaAMasayoshiTNodaK.Skin permeability of nonsteroidal antiinflammatory drugs in man. Life Sci1986: 39: 1043–1050.
13.
. DavisAFHadgraftJ.Supersaturated solutions as topical drug delivery systems. In: Pharmaceutical Skin Penetration Enhancement (WaltersKAHadgraftJ eds.), 1993Marcel DekkerNew York, pp 243–267.
14.
. BrainKRWaltersKAMolecular modeling of skin permeation enhancement by chemical agents. In: Pharmaceutical Skin Penetration Enhancement (WaltersKAHadgraftJ eds.), 1993Marcel DekkerNew York, pp 389–416.
15.
. SamourCMDonarumaLGDaskalakisSFultonBSMartyJ-PDervaultAMChanezJFDoueetO.SEPAs, a new class of percutaneous absorption enhancers. Proc Int Symp Contr Rel Bioact Mat1989; 16: 183–184.
16.
. PelhamRWSamourCMSEPA-009 - safety and efficacy studies of a broad spectrum transdermal enhancer. Proc Int Symp Contr Rel Bioact Mat1995; 22: 694–695.
17.
. BalfourJAHeelRCTransdermal estradiol: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of menopausal complaints. Drugs1990; 40: 561–582.
18.
. PowersMSSchenkelLDarleyPEGoodWRBalestraJCPlaceVAPharmacokinetics and pharmacodynamics of transdermal dosage forms of 17β-estradiol: comparison with conventional oral estrogens used for hormone replacement. Am J Obst Gyn1985; 152: 1099–1106.
19.
. WaltersKABrainKRGreenDMJamesVJWatkinsonACSandsRHComparison of the transdermal delivery of oestradiol from two gel formulations. Maturitas1998 (in press).
20.
. GoodWRPowersMSCampbellPSchenkelL.A new transdermal delivery system for estradiol. J Contr Rel1985; 2: 89–97.
21.
. CheangASitruk-WareRUtianWHA risk-benefit appraisal of transdermal estradiol therapy. Drug Safety1993; 9: 365–379.
22.
. HirvonenECacciatoreBWahlstromTRitaFWilen-RosenqvistG.Effects of transdermal oestrogen therapy in post menopausal women: a comparative study of an oestradiol gel and an oestradiol delivering patch. Br J Obstet Gynaecol1997104, suppl 16, 626–31
23.
. FieldCSOrySJWahnerHWHerrmannRRJuddHLRiggsBLPreventive effects of transdermal 17β-estradiol on osteoporotic changes after surgical menopause: a two-year placebo-controlled trial. Am J Obstet Gynecol1993; 168: 114–121.
24.
. WiklundIBergGHammarMKarlbergJLindgrenRSandinK.Longterm effect of transdermal hormonal therapy on aspects of quality of life in postmenopausal women. Maturitas1992; 14: 225–236.
25.
. PangSCGreendaleGACedarsMIGamboneJCLozanoKEggenaPJuddHLLong-term effects of transdermal estradiol with and without medroxyprogesterone acetate. Fertil Steril1993; 59: 76–82.
26.
. LindgrenRRisbergBHammarMBergGPryse-DaviesJ.Endometrial effects of transdermal estradiol/norethisterone acetate. Maturitas1992; 15: 71–78.
27.
. WisemanLRMcTavishD.Transdermal estradiol/norethisterone. A review of its pharmacological properties and clinical use in postmenopausal women. Drugs & Aging1994; 4: 238–256.
